JP Morgan Chase
CCCC icon

JP Morgan Chase’s C4 Therapeutics CCCC Stock Holding History

JP Morgan Chase’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.57M Buy
3,223,054
+3,217,109
+54,115% +$7.58M ﹤0.01% 2941
2025
Q4 		$11.4K Buy
5,945
+1,516
+34% +$3.59K ﹤0.01% 6634
2025
Q3 		$9.83K Sell
4,429
-177
-4% -$425 ﹤0.01% 6646
2025
Q2 		$6.59K Sell
4,606
-29,813
-87% -$43.4K ﹤0.01% 6382
2025
Q1 		$55.1K Buy
34,419
+1,010
+3% +$3.01K ﹤0.01% 5848
2024
Q4 		$120K Buy
33,409
+7,630
+30% +$37.9K ﹤0.01% 5684
2024
Q3 		$147K Buy
25,779
+786
+3% +$4.73K ﹤0.01% 5536
2024
Q2 		$115K Buy
24,993
+24,987
+416,450% +$149K ﹤0.01% 5442
2024
Q1 		$49 Sell
6
-6,887
-100% -$53.4K ﹤0.01% 7043
2023
Q4 		$38.9K Sell
6,893
-2,242
-25% -$5.11K ﹤0.01% 6072
2023
Q3 		$17K Buy
9,135
+7,632
+508% +$23.3K ﹤0.01% 6108
2023
Q2 		$4.13K Sell
1,503
-32,360
-96% -$104K ﹤0.01% 6205
2023
Q1 		$107K Sell
33,863
-66,619
-66% -$392K ﹤0.01% 5396
2022
Q4 		$592K Buy
100,482
+74,117
+281% +$615K ﹤0.01% 4405
2022
Q3 		$231K Buy
26,365
+1,583
+6% +$16.4K ﹤0.01% 4880
2022
Q2 		$187K Sell
24,782
-44,638
-64% -$393K ﹤0.01% 5110
2022
Q1 		$1.68M Buy
69,420
+40,698
+142% +$988K ﹤0.01% 3894
2021
Q4 		$925K Sell
28,722
-26,107
-48% -$1.03M ﹤0.01% 4453
2021
Q3 		$2.45M Buy
54,829
+38,293
+232% +$1.64M ﹤0.01% 3624
2021
Q2 		$625K Buy
16,536
+10,325
+166% +$370K ﹤0.01% 4561
2021
Q1 		$230K Buy
6,211
+1,424
+30% +$56.6K ﹤0.01% 5089
2020
Q4 		$159K Buy
+4,787
New +$139K ﹤0.01% 4881

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's CCCC Position: Q1 2026 in Review

JP Morgan Chase increased its C4 Therapeutics (CCCC) stake by 54,115% in Q1 2026, buying an estimated $7.58M and bringing the position to 3,223,054 shares worth $7.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

JP Morgan Chase first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • JP Morgan Chase held 3,223,054 shares of C4 Therapeutics worth $7.57M as of Q1 2026.
  • JP Morgan Chase bought 3,217,109 C4 Therapeutics shares in Q1 2026, an estimated $7.58M.
  • C4 Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2941 holding.
  • JP Morgan Chase first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.